Skip to Main content Skip to Navigation
New interface
Journal articles

Le sulfure d’hydrogène : une thérapeutique d’avenir dans la neuroprotection post-arrêt cardiorespiratoire ?

Abstract : Each year, in France, the number of cardiac arrests is evaluated between 30,000 to 50,000. When a patient survives, he undergoes a post-resuscitation syndrome which can aggravate the injuries and for which nowadays, no medication is available. In some kinds of cardiac arrest, a hypothermia protocol can be applied with a need for monitoring because of the appearance of side effects. In this context, hydrogen sulfide, which is a gasotransmitter with numerous physiological and pharmacological properties, may be interesting. Indeed, its use could protect against oxidative, inflammatory and apoptotic troubles induced by the post-resuscitation syndrome. The implied biochemical mechanisms are adenosine triphosphate potassium channels activation and cytochrome c oxidase inhibition. This molecule can also induce a suspended animation state characterized by a metabolism decrease, which could give a delay for physicians to start a therapeutic monitoring. Thus, in spite of a modest and sometimes contradictory literature, this compound could become the first neuroprotective molecule in cardiac arrest.
Document type :
Journal articles
Complete list of metadata
Contributor : Cithefor UL Connect in order to contact the contributor
Submitted on : Tuesday, March 22, 2016 - 11:19:44 AM
Last modification on : Friday, September 10, 2021 - 1:04:03 PM




Houssine Sayouri, Ariane Boudier, Claude Vigneron, Pierre Leroy, Serge Le Tacon. Le sulfure d’hydrogène : une thérapeutique d’avenir dans la neuroprotection post-arrêt cardiorespiratoire ?. Annales Pharmaceutiques Françaises, 2015, 73 (6), pp.401-410. ⟨10.1016/j.pharma.2015.04.005⟩. ⟨hal-01291860⟩



Record views